Sa A Wang, MD

Professor, hematopathologist, Medical director of flow cytometry at MD Anderson. Associate Editor of Clinical Cytometry B

[Sa A Wang, MD @SaWangMD]

Have an interesting flow cytometry case? Submit your case, share your experience, and join us at the MD Anderson Flow Cytometry Conference this September.

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Our department is hosting a fantastic flow cytometry course Sep 19-20 2026.
Register and join!! This course will be great for those interested in advancing their flow skills, particularly in panel design and MRD.
@MDAndersonnews
https://t.co/KqNxuRnm6S

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Our department is hosting a fantastic flow cytometry course Sep 19-20 2026.
Register and join!! This course will be great for those interested in advancing their flow skills, particularly in panel design and MRD.
@MDAndersonnews
https://t.co/KqNxuRnm6S

[Sa A Wang, MD @SaWangMD]

Looking at the background reactive B and T cells, may help you to suspect types of lymphoma that you are often not able to identify the neoplastic tumor cells by routine flow cytometry. Johnathan Fromm at ICCS-24

[Sa A Wang, MD @SaWangMD]

The different immunophenotype of PDC-AML, BPDCN and MPDCP(mature plasmacytoid dendritic cell proliferation) by Wei wang from MD Anderson at ICCS

[Sa A Wang, MD @SaWangMD]

Nice summary of flow and NGS discordance for B-Lymphoblastic leukemia by Brent Wood

[Sa A Wang, MD @SaWangMD]

Not all CD22 monoclonal antibodies are born equal, some recognized basophils and plasmacytoid dendritic cells in addition to B cells, and some recognize them all. By Misha Roshal

[Sa A Wang, MD @SaWangMD]

CD38 nanoantibody JK36, excellent in identifying plasma cells in myeloma post antiCD38 directed therapy

[Sa A Wang, MD @SaWangMD]

MRD >0.1% is considered as treatment failure in AML by ELN.

[Sa A Wang, MD @SaWangMD]

ELN guideline for AML MRD by Sylvia Freeman. So lucky to get her here this year ICCS-2024

[Sa A Wang, MD @SaWangMD]

It is a T-ALL arising from thymoma!

[Sa A Wang, MD @SaWangMD]

The second day of ICCS, CSI case with differential diagnosis between thymine vs T-lymphoblastic lymphoma by Christian Hirt from Stanford

[Sa A Wang, MD @SaWangMD]

This year’s Wallace Coulter award goes to Sindhu CherianMD, well deserved and congratulations!

[Sa A Wang, MD @SaWangMD]

Well, the last talk on the CART is a bit off the interest of flow cytometry, but the last slide is useful.

[Sa A Wang, MD @SaWangMD]

Flow cytometry measurements of CART help to manage patients who are undergoing CART therapy. Summary slide from Dr. Kathleen Gallagher. Proud that we have CAR19, BCMA CART and allogenic CART tests at MA Anderson as CLIA assays

[Sa A Wang, MD @SaWangMD]

Kick off the 39 th ICCS meeting with the first session on CART. First talk by Mark Leick from MGH, here are the FDA approved CART

[Sa A Wang, MD @SaWangMD]

The deadline of application is 29th. There is a significant reduction of registration for remote access to the ICCS meeting

[ICCS_Education @ICCS_Education]

ICCS also offers educational grants for people from developing countries to remotely attend the #FlowICCS23 Meeting. Deadline to apply is August 29th.

Please visit link for additional information: https://t.co/Kj3FlF2Pfi

[Sa A Wang, MD @SaWangMD]

Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach https://t.co/I1H3XkNdxq

[Rashmi Kanagal-Shamanna, MD @kanagalshamanna]

Case submission for the SH-EAHP @SocforHemepath Workshop 2023 is now open!

Link: https://t.co/1P5EpVBlkq

➡️ Looking for “T & NK-cell lymphomas”
✨Don’t forget to include unstained sections, we will select a subset for genomic profiling to provide molecular 🧬classification.

[Sa A Wang, MD @SaWangMD]

Congrats and to other fellows of MDACC @KarenNahmod

[Aakash Bhatia, MD @SkybhatiaMD]

Board Certified Hematopathologist !! 🥳

[Sa A Wang, MD @SaWangMD]

@ananthvikas @drkunalsehgal @PrashantTembha1 @DrArunCMC @LakshmiKoulmane @P_G_Subramanian @DrAnilHandoo @khaliqurrahman Yes, that is our study